Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | DHFR | P00374 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317100 | 0.80 | CD74 (0.79) | NPC1KDM4ERAB9APKMLMNA | |
| SCHEMBL3319480 | 0.80 | CD74 (0.79) | NPC1KDM4ERAB9APKMLMNA | |
| SCHEMBL6428720 | 0.79 | CD74 (0.77) | NPC1KDM4ERAB9APKMLMNA | |
| SCHEMBL28200632 | 0.79 | CD74 (0.77) | NPC1KDM4ERAB9APKMLMNA | |
| SCHEMBL31300953 | 0.77 | KDM4E (0.57) | NPC1KDM4ERAB9AGRM4PKM | |
| SCHEMBL19076207 | 0.76 | KMT2A (0.68) | NPC1KDM4ERAB9AGRM4PKM | |
| SCHEMBL27470619 | 0.76 | KMT2A (0.68) | NPC1KDM4ERAB9AGRM4PKM | |
| Naphthalene SCHEMBL28861971 | 0.76 | CCR1 (0.59) | NPC1KDM4ERAB9ALMNAMEN1 | |
| SCHEMBL10665839 | 0.73 | GRM4 (0.73) | NPC1KDM4ERAB9AGRM4PKM | |
| SCHEMBL10665836 | 0.73 | GRM4 (0.73) | NPC1KDM4ERAB9AGRM4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906193-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | disclosed |
| US-20040053964-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| EP-1339689-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002036568-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053964-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | NPC1 2171/4885KDM4E 4425/4885RAB9A 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.